Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 6/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 5/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Filaminast SCHEMBL73844 | 1.00 | PDE4D (1.00) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| Filaminast SCHEMBL73843 | 1.00 | PDE4D (1.00) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| Filaminast SCHEMBL13986144 | 1.00 | PDE4D (1.00) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL14457690 | 0.91 | PDE4D (0.84) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL7338128 | 0.89 | PDE4D (0.80) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL7338134 | 0.89 | PDE4D (0.80) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL7341873 | 0.87 | PDE4D (0.77) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL7341870 | 0.87 | PDE4D (0.77) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| Piclamilast SCHEMBL2723503 | 0.84 | PDE4D (0.81) | PDE4DPDE4BMAPK14PDE4APDE4C | |
| SCHEMBL7370380 | 0.83 | PDE4B (0.71) | PDE4DPDE4BMAPK14PDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| EP-3806888-B1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116726362-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11666642-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230074330-A1 | PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-20220403001-A1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11241485-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4D 10/4885PDE4B 3/4885MAPK14 1376/4885 |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | PDE4D 660/4885PDE4B 594/4885MAPK14 4519/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | PDE4D 2672/4885PDE4B 3135/4885MAPK14 4786/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | PDE4D 660/4885PDE4B 594/4885MAPK14 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.